logo
Sign in

MRNA Stock Price, Chart, Stats & News

Moderna, Inc.
Save
23.55B
Market cap
Current P/E
23.04x
Forward P/E

MRNA chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
14.10%
Operating margin
-158.21%
Pretax margin
-142.46%
Net margin
-145.24%
Effective tax rate
-1.95%
ROA
-22.87%
ROE
-30.15%
D/E
0.22x
Interest coverage ratio
-1537.00x

MRNA valuation

P/E
P/S
10.07x
P/B
2.25x
P/CF
-10.49x
P/FCF
-9.53x
P/OCF
-10.49x
PEG
-0.69x
EV multiple
-7.94x

About

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah.

Similar securities

Based on sector and market capitalization

Report issue